# Neurotech Pharmaceuticals, Inc.

> Neurotech Pharmaceuticals is a Cumberland, Rhode Island biotechnology company that develops long-acting therapies for chronic retinal diseases using its Encapsulated Cell Technology (ECT) platform - a tiny implant of genetically engineered cells that continuously secretes a therapeutic protein inside the eye. In March 2025 its lead product ENCELTO (revakinagene taroretcel-lwey, formerly NT-501/Renexus) became the first and only FDA-approved treatment for macular telangiectasia type 2 (MacTel), delivering ciliary neurotrophic factor (CNTF) to slow the loss of photoreceptors.

- **Founded:** 2000
- **Headquarters:** Cumberland, Rhode Island, United States
- **Founders:** Richard Small (Chief Executive Officer (since Dec 2017; former CFO/COO))
- **Team size:** ~130 employees
- **Products:** ENCELTO (revakinagene taroretcel-lwey), NT-501 / Renexus, Encapsulated Cell Technology (ECT) platform, NT-503
- **Notable:** Won FDA approval for ENCELTO in March 2025 - the first and only approved treatment for macular telangiectasia type 2., First company to bring an encapsulated cell therapy to market., Received FDA Fast Track designation and Priority Review for NT-501.

## Products & services

- **ENCELTO (revakinagene taroretcel-lwey)** — First and only FDA-approved treatment for macular telangiectasia type 2 (MacTel). An allogeneic encapsulated cell therapy implant that continuously delivers ciliary neurotrophic factor (CNTF) to the retina to slow photoreceptor loss.
- **NT-501 / Renexus** — The clinical-stage designation for the encapsulated cell implant that became ENCELTO; delivers CNTF from human-derived cells encapsulated in a semipermeable hollow-fiber membrane.
- **Encapsulated Cell Technology (ECT) platform** — Proprietary platform in which genetically engineered cells are sealed in a semipermeable capsule that lets in oxygen and nutrients, keeps out immune cells, and secretes a chosen therapeutic protein for years.
- **NT-503** — Earlier ECT program engineered to deliver an anti-VEGF agent for wet AMD; part of the company's broader pipeline history.

## Achievements

- Won FDA approval for ENCELTO in March 2025 - the first and only approved treatment for macular telangiectasia type 2.
- First company to bring an encapsulated cell therapy to market.
- Received FDA Fast Track designation and Priority Review for NT-501.
- Secured a permanent CMS J-code (J3403) effective October 1, 2025.
- Opened its own GMP manufacturing facility in Cumberland, Rhode Island.
- Surpassed 100 surgical procedures and 700+ patients in its patient portal within a year of launch.

## Latest updates

- **2026-03** — Neurotech provided a corporate update marking the first anniversary of ENCELTO's approval, citing expanding physician adoption and patient access.
- **2025-10** — CMS permanent J-code (J3403) for ENCELTO took effect, with ~88 medical policies covering roughly 200 million lives.
- **2025-06** — ENCELTO began its US commercial rollout, supported by exclusive distributor Cencora.
- **2025-03** — FDA approved ENCELTO (revakinagene taroretcel-lwey) for MacTel type 2.

## Links

- Website: https://neurotechpharmaceuticals.com
- LinkedIn: http://www.linkedin.com/company/neurotechpharmaceuticals
- Twitter/X: https://twitter.com/NeurotechPharma
- Instagram: https://www.instagram.com/neurotechpharma

---

Profile page: https://yespress.io/neurotech-pharmaceuticals-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-18